AYTU BIOPHARMA, INC Debt Instrument, Fee Amount
AYTU BIOPHARMA, INC (AYTU) had Debt Instrument, Fee Amount of $638.00 thousand as of 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFeeAmount · last filed 2023-11-14
- 2023-09-30: Debt Instrument, Fee Amount $638.00K.
- 2023-06-30: Debt Instrument, Fee Amount $638.00K.
- 2023-03-31: Debt Instrument, Fee Amount $638.00K.
- 2022-12-31: Debt Instrument, Fee Amount $638.00K.
| Period end | Debt Instrument, Fee Amount |
|---|---|
| 2023-09-30 | $638.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $638.00K 10-K · filed 2023-10-12 |
| 2023-03-31 | $638.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $638.00K 10-Q · filed 2023-02-21 |
| 2022-09-30 | $638.00K 10-Q/A · filed 2023-02-21 |
| 2022-06-30 | $638.00K 10-Q · filed 2023-05-11 |
| 2022-03-31 | $638.00K 10-Q · filed 2022-05-16 |
| 2022-01-26 | $600.00K 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |